There are now well over half a billion complete DNA sequences in Genbank, the largest public repository of DNA information.
In fact, the global DNA ecosystem is estimated to be at least 53 nonillion (5.3 × 1031) megabase pairs with a total mass exceeding 50 billion tons.
That’s a lot of DNA data.
Arcanabio develops technologies that allow scientists and researchers to navigate efficiently through DNA data and drive the development of new diagnostics and ways to stop diseases
More data means we can develop better DNA tests. Arcanabio makes technology needed to transform DNA data efficiently into diagnostics.
We are passionate about developing new ways to analyze DNA to drive the diagnosis, prevention and treatment of infectious diseases.
Bacteria, viruses and other pathogens are associated with an economic burden of over $120 billion in the U.S with the growing threat of antibiotic resistant infections costing Americans over $20 billion in direct medical costs, and over $35 billion in lost productivity.
An earlier version of the Arcanabio software was used to develop the first FDA approved test for the Zika virus in 2016. Today our system designs DNA tests for a wide range of microbes of concern to human health.
Arcanabio developes disruptive technologies for handling large DNA datasets combined with best-in-class high performance computational biology.
We can work with data from public databases, or project-specific Next Generation Sequencing (NGS) projects to identify regions of interest. Our goal is to get data analyzed and organized efficiently so you can focus on what matters the most.